Back to News
Market Impact: 0.1
RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial
Source: GlobeNewswire
Healthcare & Biotech
A University of Vermont-sponsored investigator-initiated trial is exploring TAMP utilization before surgical resection in a new clinical setting. The headline provides no trial results, patient numbers, or other details on potential clinical or commercial impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- Profound Medical stock surges 20% on raised Q3 revenue outlook
- Medical device maker Centinel Spine discloses revenue rise in US IPO filing
- Halozyme stock rises after winning injunction against Merck
- BTIG cuts ArriVent BioPharma stock price target on trial results
- MustGrow Biologics at 20th iif: sales grow as Bayer backs pipeline
- Healthcare Services Group acquires NEXDINE Hospitality for $93.5M